Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXT-m200 for Methamphetamine Overdose Toxicity
NCT04715230Phase 2Terminated
- Sponsor
- InterveXion Therapeutics
- Start
- Jun 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of devextinetug in methamphetamine intoxication, sponsored by InterveXion Therapeutics. Started Jun 2021; status: terminated.
02
Drugs
devextinetug
03
Conditions
methamphetamine intoxication
Beyond the preview
Go deeper on NCT04715230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715230.